Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Spatial multi-omics for target discovery: What the data actually shows

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Source

Read at drugdiscoverynews.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Spatial multi-omics integrates spatial transcriptomics, proteomics, and metabolomics to provide more reliable target discovery by overcoming individual layer limitations through combined molecular and functional phenotype measurement.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You can now de-risk target hypotheses by integrating protein and RNA spatial data, avoiding costly blind spots single-layer methods miss. If you're developing drug targets, invest in multi-omics platforms that combine proteomics and transcriptomics for more accurate insights.

◆ Coverage

1 source · 17 Aug 2026

◆ Related on Wire

◆ Topics

Drug Discoverymulti-omicstarget-discoveryspatial-transcriptomicsspatial-proteomicsbiotech